longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Dogwood Therapeutics

DWTX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • DWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly Growth

    Investing.com·Jan 23, 2025 at 04:59 PM
    - Virios Therapeutics Llc (DWTX) stock has reached a 52-week high of $15.74, with a market capitalization of approximately $18 million and a gain of over 45% in the past week. - Analyst targets for the stock vary from $5 to $25, indicating differing opinions on its potential, while the stock is considered overvalued according to InvestingPro's Fair Value analysis. - In contrast, Dogwood Therapeutics faces potential Nasdaq delisting due to equity shortfalls but remains optimistic about regaining compliance and advancing its research pipeline, including studies on Long-COVID and chemotherapy-induced neuropathic pain.
    DWTX+3.19%
  • Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025

    StockTitan·Jan 21, 2025 at 03:38 PM
    - Dogwood Therapeutics plans to start patient dosing in Q1 2025 for its Phase 2b clinical trial of Halneuron®, a Nav 1.7 inhibitor aimed at treating chemotherapy-induced neuropathic pain. - The drug has previously shown significant pain reduction and a favorable safety profile in over 700 patients, with no addiction potential. - With one-third of patients experiencing chronic neuropathy from certain chemotherapeutics and no approved treatments available, the CINP market presents a $1.5B opportunity for the company.
    DWTX+3.19%